Acute Acneiform Eruption Related to Cetuximab Treated Successfully with Oral Tetracycline

Creative Commons License

Metin M. S., Kızılyel O., Elmas O. F., Özdemir Ş., Bilen H.

ASTIM ALLERJI IMMUNOLOJI, cilt.15, sa.3, ss.158-161, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.21911/aai.23
  • Dergi Adı: ASTIM ALLERJI IMMUNOLOJI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.158-161
  • Atatürk Üniversitesi Adresli: Evet

Özet

The most common known causes of acneiform lesions secondary to chemotherapy are epidermal growth factor receptor (EGFR) inhibitors. Cetuximab and panitumumab which are monoclonal antibodies and gefitinib and erlotinib which are tyrosine kinase inhibitors are the major drugs in this group. An acneiform lesion is the most common and the earliest reaction among the dermatological side effects related to EGFR inhibitors. Acneiform eruption, asthenia, stomach ache and nausea-vomiting are side effects related to cetuximab. We reported a 59-year-old man who presented with sudden acneiform lesions on his face, neck and chest at the 8th day of cetuximab treatment which was used for metastatic colon cancer. We reported this case to share that it is possible to treat acneiform eruption related to cetuximab with oral tetracycline, topical ketoconazole, local clindamycin phosphate and benzoyl peroxide.